Macular Degeneration Home > Lucentis and Pregnancy
No clinical studies have been conducted on Lucentis and pregnancy; therefore, the drug has been given a pregnancy Category C rating (meaning there are potential risks involved). Since Lucentis is used for treating a condition that generally affects older people, it is unlikely that a young woman would take the drug. However, if you are taking Lucentis and pregnancy occurs, alert your healthcare provider immediately.
It is unknown if Lucentis® (ranibizumab) is safe for use during pregnancy. It is a medication used for wet macular degeneration and macular edema, conditions that most likely affect older people.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans but that do appear to cause harm to fetuses in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
Lucentis was given a pregnancy Category C rating because it has not been studied at all in any pregnant women or animals.